Advertisement

Advertisement

INCY Stock Latest News

Incyte, Genesis Molecular AI announce expansion of collaboration

The FlyIncyte, Genesis Molecular AI announce expansion of collaboration

Incyte, Edison Scientific announce strategic collaboration to employ Kosmos

PremiumThe Fly

Incyte, Edison Scientific announce strategic collaboration to employ Kosmos

2d ago

Incyte Targets KRAS G12D Pancreatic Cancer With New Phase 3 DAWN-303 Trial

PremiumCompany Announcements

Incyte Targets KRAS G12D Pancreatic Cancer With New Phase 3 DAWN-303 Trial

13d ago

Incyte announces 24-week long-term data from Phase 3 TRuE-AD4 trial

PremiumThe Fly

Incyte announces 24-week long-term data from Phase 3 TRuE-AD4 trial

14d ago

Incyte gets orphan designation for treatment of pancreatic cancer

PremiumThe Fly

Incyte gets orphan designation for treatment of pancreatic cancer

17d ago

MacroGenics, Sagard enter expanded Zynyz royalty purchase agreement

PremiumThe FlyMacroGenics, Sagard enter expanded Zynyz royalty purchase agreement

17d ago

Incyte announces FDA approval of Jakari XR

The Fly

Incyte announces FDA approval of Jakari XR

20d ago

Incyte price target raised to $90 from $84 at Oppenheimer

The Fly

Incyte price target raised to $90 from $84 at Oppenheimer

22d ago

Incyte price target raised to $123 from $120 at Stifel

PremiumThe Fly

Incyte price target raised to $123 from $120 at Stifel

22d ago

Incyte price target raised to $124 from $121 at BofA

PremiumThe Fly

Incyte price target raised to $124 from $121 at BofA

22d ago

Incyte: Buy Rating Reaffirmed as Pipeline Strength and Long-Term Visibility Drive Price Target Increase to $124

PremiumRatings

Incyte: Buy Rating Reaffirmed as Pipeline Strength and Long-Term Visibility Drive Price Target Increase to $124

22d ago

Incyte Earnings Call Highlights Broad Growth, Rising Risks

PremiumCompany Announcements

Incyte Earnings Call Highlights Broad Growth, Rising Risks

23d ago

Incyte sees FY26 revenue $4.77B-$4.94B, consensus $5.57B

PremiumThe FlyIncyte sees FY26 revenue $4.77B-$4.94B, consensus $5.57B

23d ago

Incyte appoints Suketu Upadhyay as CFO

The Fly

Incyte appoints Suketu Upadhyay as CFO

23d ago

Incyte reports Q1 EPS $1.81, consensus $1.34

The Fly

Incyte reports Q1 EPS $1.81, consensus $1.34

23d ago

INCY Earnings Report this Week: Is It a Buy, Ahead of Earnings?

PremiumPre-Earnings

INCY Earnings Report this Week: Is It a Buy, Ahead of Earnings?

25d ago

Incyte, BNY Mellon, Quantum-Si, Jabil, Levi Shock

PremiumWeekend Updates

Incyte, BNY Mellon, Quantum-Si, Jabil, Levi Shock

26d ago

Incyte to announce full results from Phase 3 tafasitamab study at ASCO

PremiumThe Fly

Incyte to announce full results from Phase 3 tafasitamab study at ASCO

1M ago

Bullish View on Povorcitinib’s Broad HS Adoption and Manageable JAK Safety Supports $135 Target

PremiumRatings

Bullish View on Povorcitinib’s Broad HS Adoption and Manageable JAK Safety Supports $135 Target

1M ago

Incyte price target raised to $95 from $92 at RBC Capital

PremiumThe FlyIncyte price target raised to $95 from $92 at RBC Capital

1M ago

Incyte Announces Upcoming Resignation of Board Member Schaffert

Company Announcements

Incyte Announces Upcoming Resignation of Board Member Schaffert

2M ago

Incyte announces new 54-week data on safety, efficacy of povorcitinib

The Fly

Incyte announces new 54-week data on safety, efficacy of povorcitinib

2M ago

Trending

S&P 500

―

Dow Jones

―

Nasdaq 100

―

More Trending Stocks >